Biotav Shield Ltd.

Biotav is leveraging three decades of research, development, and manufacturing of various solutions for emerging infectious diseases, Biotav is based in veterinary medicine and adapted to human medicine. The company has been implementing the ‘One Health’ approach to innovative and develop breakthrough solutions and has acquired unparalleled knowledge and experience in the field. Led by a highly experienced expert team, familiar not only with the relevant biology and pathology, but also with the market and regulatory climate, Biotav is currently developing an oncological viral treatment for brain tumors, as well as a vaccine and treatment for COVID-19. With provisional patents in hand and applications pending, a top-of-the-line production facility operating in accordance with GMP standards, and an elaborate network of connections with top institutes and government offices, Biotav is uniquely positioned to transform the manner in which emerging infectious diseases are treated.